Summary
With this acquisition Abbott establishes its position as a major player in the field of interventional cardiology and treatment of structural heart disease.
The field of structural heart disease therapy is the fastest growing area of interventional cardiology and Abbott is getting in at the ground floor.
In addition to Edwards and Medtronic which have aortic valve stents in the pipeline, the Evalve system is the most advanced valve repair system.
Analysis
The field of interventional cardiology is changing and coronary vascular interventions are replaced by interventions to repair heart valves or to repair defects in the interatrial and interventricular septum.
While Cordis and Boston Scientific have led the way in coronary intervention devices, Abbott and Medtronic are now offering new generation stents and devices for structural heart disease therapy.
The acquisition of Evalve was the logical next step for Abbott in its quest to become a leading company in interventional cardiovascular therapeutics.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
